Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Total Non-Current Liabilities (2019 - 2025)

UroGen Pharma's Total Non-Current Liabilities history spans 7 years, with the latest figure at $302.0 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 3.89% year-over-year to $302.0 million; the TTM value through Dec 2025 reached $302.0 million, up 3.89%, while the annual FY2025 figure was $302.0 million, 3.89% up from the prior year.
  • Total Non-Current Liabilities reached $302.0 million in Q4 2025 per URGN's latest filing, up from $296.7 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $302.0 million in Q4 2025 to a low of $18.2 million in Q1 2021.
  • Average Total Non-Current Liabilities over 5 years is $213.2 million, with a median of $231.7 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: soared 888.39% in 2022, then rose 3.89% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $108.5 million in 2021, then surged by 104.59% to $222.0 million in 2022, then rose by 8.27% to $240.3 million in 2023, then increased by 20.97% to $290.7 million in 2024, then rose by 3.89% to $302.0 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Total Non-Current Liabilities are $302.0 million (Q4 2025), $296.7 million (Q3 2025), and $298.3 million (Q2 2025).